Civic Intelligence

Plasma Protein Therapeutics Association

990 • Fiscal year 2014 • EIN 52-1800187

Jan 01, 2014 to Dec 31, 2014 • Filed on Nov 12, 2015

Organization ProfileWWW.PPTAGLOBAL.ORG

View Organization Page

147 Old Solomons Island Rd No 100Annapolis, MD 21401

(443) 458-4668

Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

67th percentile

0.42x

Higher debt load relative to assets than 67% of similar nonprofits.

2014 filings • 501(c)6 • $10M-$25M nonprofits • Source year 2014

Liabilities / Revenue

30th percentile

0.21x

Higher debt load relative to revenue than 30% of similar nonprofits.

2014 filings • 501(c)6 • $10M-$25M nonprofits • Source year 2014

Net Margin

38th percentile

3.2%

Higher net margin than 38% of similar nonprofits.

2014 filings • 501(c)6 • $10M-$25M nonprofits • Source year 2014

Top Officer Pay

70th percentile

$481,552

Higher top officer pay than 70% of similar nonprofits.

Top officer pay equals 4.5% of source-year revenue.

2014 filings • 501(c)6 • $10M-$25M nonprofits • Source year 2014

Asset Growth

53rd percentile

6.6%

Faster asset growth than 53% of similar nonprofits.

2014 filings • 501(c)6 • $10M-$25M nonprofits • Annualized from 2013 to 2014

Revenue Growth

36th percentile

2.2%

Faster revenue growth than 36% of similar nonprofits.

2014 filings • 501(c)6 • $10M-$25M nonprofits • Annualized from 2013 to 2014

Balance Sheet
Liabilities / Assets67th percentile

Assets

Up

$5,430,703

Up $334,544 (+6.6%) from 2013

Net Assets

Up

$3,165,958

Up $342,931 (+12%) from 2013

Liabilities

Down

$2,264,745

Down $8,387 (-0.4%) from 2013

Revenue And Expenses
Liabilities / Revenue30th percentileNet Margin38th percentile

Revenue

Up

$10,668,958

Up $228,307 (+2.2%) from 2013

Expenses

Down

$10,328,608

Down $638,834 (-5.8%) from 2013

Net Income

Up

$340,350

Up $867,141 (+165%) from 2013

Historical Trend

Balance Sheet Trend

Asset Growth53rd percentile

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$15M$10M$5.0M$0Assets 2011: $5,872,580Liabilities 2011: $1,878,186Net Assets 2011: $3,994,3942011Assets 2012: $6,036,904Liabilities 2012: $2,741,834Net Assets 2012: $3,295,0702012Assets 2013: $5,096,159Liabilities 2013: $2,273,132Net Assets 2013: $2,823,0272013Assets 2014: $5,430,703Liabilities 2014: $2,264,745Net Assets 2014: $3,165,9582014Assets 2015: $6,180,058Liabilities 2015: $1,889,120Net Assets 2015: $4,290,9382015Assets 2016: $7,586,366Liabilities 2016: $2,204,466Net Assets 2016: $5,381,9002016Assets 2017: $9,064,774Liabilities 2017: $3,119,114Net Assets 2017: $5,945,6602017Assets 2018: $8,009,116Liabilities 2018: $3,039,730Net Assets 2018: $4,969,3862018Assets 2019: $9,097,478Liabilities 2019: $3,320,536Net Assets 2019: $5,776,9422019Assets 2020: $9,829,180Liabilities 2020: $2,958,793Net Assets 2020: $6,870,3872020Assets 2021: $7,828,244Liabilities 2021: $2,472,210Net Assets 2021: $5,356,0342021Assets 2022: $10,684,709Liabilities 2022: $2,287,926Net Assets 2022: $8,396,7832022Assets 2023: $12,157,727Liabilities 2023: $3,203,661Net Assets 2023: $8,954,0662023Assets 2024: $12,791,836Liabilities 2024: $4,737,253Net Assets 2024: $8,054,5832024

Highlighted filing

2014

Assets$5,430,703
Liabilities$2,264,745
Net Assets$3,165,958
Open 2014 Filing

Operations Trend

Revenue Growth36th percentile

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$20M$15M$10M$5.0M$0-$5.0MRevenue 2011: $10,275,122Expenses 2011: $10,323,938Net Income 2011: -$48,8162011Revenue 2012: $10,421,071Expenses 2012: $11,090,817Net Income 2012: -$669,7462012Revenue 2013: $10,440,651Expenses 2013: $10,967,442Net Income 2013: -$526,7912013Revenue 2014: $10,668,958Expenses 2014: $10,328,608Net Income 2014: $340,3502014Revenue 2015: $11,388,208Expenses 2015: $10,041,196Net Income 2015: $1,347,0122015Revenue 2016: $11,663,757Expenses 2016: $10,572,795Net Income 2016: $1,090,9622016Revenue 2017: $12,405,288Expenses 2017: $11,841,528Net Income 2017: $563,7602017Revenue 2018: $12,691,109Expenses 2018: $13,667,383Net Income 2018: -$976,2742018Revenue 2019: $13,365,635Expenses 2019: $12,558,079Net Income 2019: $807,5562019Revenue 2020: $12,381,256Expenses 2020: $11,287,811Net Income 2020: $1,093,4452020Revenue 2021: $13,003,501Expenses 2021: $14,517,854Net Income 2021: -$1,514,3532021Revenue 2022: $16,106,524Expenses 2022: $13,065,775Net Income 2022: $3,040,7492022Revenue 2023: $15,001,344Expenses 2023: $14,444,061Net Income 2023: $557,2832023Revenue 2024: $14,975,704Expenses 2024: $16,177,207Net Income 2024: -$1,201,5032024

Highlighted filing

2014

Revenue$10,668,958
Expenses$10,328,608
Net Income$340,350
Open 2014 Filing
Jump To
Filing Snapshot
Filing Period
Jan 1, 2014 to Dec 31, 2014
Signed
Nov 12, 2015
Return Version
2014v5.0
Gross Receipts
$10,668,958
Mission and Program Overview

Mission

THE PLASMA PROTEIN THERAPEUTICS ASSOCIATION SERVES AS the cornerstone for consensus development of industry-wide initiatives and is the primary advocate for the leading producers of plasma-based and related recombinant biological therapeutics. the association's mission is to promote an environment that fosters the availability of safe and effective plasma protein Therapeutics. As the global representative for the plasma therapeutics industry, the Association works cooperatively with patient groups, legislators, regulatory agencies and others to address critical issues that impact the industry and those people who depend on plasma protein therapeutics. The Association's global committees and regional working groups bring together industry experts to focus on important issues relating to the quality, safety and efficacy of plasma therapeutics.

Ppta advocates and promotes safe and effective plasma protein therapeutics.

Balance Sheet Detail
LineBeginningEndChange
Assets
Savings and Temporary Cash Investments$4,454,874$4,605,828▲ $150,954
Accounts Receivable$407,635$456,313▲ $48,678
Land, Buildings, and Equipment, Net$148,031$280,780▲ $132,749
Prepaid Expenses and Deferred Charges$85,619$87,782▲ $2,163
Total Assets$5,096,159$5,430,703▲ $334,544
Liabilities
Accounts Payable and Accrued Expenses$1,418,035$1,182,718▼ $235,317
Deferred Revenue$710,775$1,082,027▲ $371,252
Other Liabilities$144,322$0▼ $144,322
Total Liabilities$2,273,132$2,264,745▼ $8,387
Net Assets / Fund Balance
Unrestricted Net Assets$2,823,027$3,165,958▲ $342,931
Total Net Assets Fund Balance$2,823,027$3,165,958▲ $342,931
Total Liabilities and Net Assets / Fund Balance$5,096,159$5,430,703▲ $334,544

Asset Categories

AssetBook ValueDepreciationBasis
Equipment$277,331$1,062,584$1,339,915
Leasehold Improvements$0$135,020$135,020
Other Land Buildings$3,449$34,713$38,162
Compensation and Service Providers
Top Officer Pay70th percentile

Employees

NameTitleFull / Part TimeBaseOtherTotal
Jan M BultPresident & CEOFT$153,547$332,748$486,295
Julie BirkoferSenior VP, North AmericaFT$250,836$105,278$356,114
Mary GustafsonVP, Regulatory PolicyFT$213,051$103,197$316,248
John DelacourtVP, Legal AffairsFT$221,251$88,424$309,675
Joshua PenrodVP, SourceFT$185,645$83,323$268,968
George SchreiberGeorge SchreiberPT$156,129$74,398$230,527
William SpeirSenior Director, State AffairsFT$150,000$74,224$224,224
Gene StroshaneControllerFT$120,000$47,338$167,338
Mike MccormickMike MccormickFT$101,795$56,224$158,019
John Crosland IiiJohn Crosland IiiFT$103,761$5,446$109,207

Board Members and Trustees

NameTitle
Paolo MarcucciGlobal Board Chairman
David BellGlobal Board Member
Karen EtchbergerGlobal Board Member
Paul Rosenthal EsqGlobal Board Member
Ronald LloydGlobal Board Member
Gregor SchulzTreasurer

Highest Paid Contractors

ContractorServicesLocationCompensation
Almar Therapeutics Pty LtdConsulting19 INVESTIGATOR STREET, Red Hill, ACT, Au$379,000
Revenue and Support

Revenue Composition

Contributions and Grants
$0
Program Service Revenue
$10,655,237
Investment Income
$2,505
Other Revenue
$11,216
Change in Net Assets
$340,350

Audited Revenue Reconciliation

Revenue per Audited Statements
$10,668,958
Revenue Not Reported on Financial Statements
$0
Revenue Not Reported on Form 990
$0
Total Revenue per Audited Statements
$10,668,958
Total Revenue per Form 990
$10,668,958
Expenses and Functional Allocation

Major Expense Lines

Line ItemAmount
Other Expenses$6,142,864
Salaries, Compensation, and Employee Benefits$4,185,744
Grants and Similar Amounts Paid$0
Professional Fundraising Fees$0
Total Fundraising Expense$0

Functional Expense Allocation

Line ItemProgramManagementFundraisingTotal
Other Salaries and Wages---$1,933,726
Current Officers, Directors, Trustees, and Key Employees---$1,588,393
All Other Expenses---$773,307
Travel---$462,536
Fees for Services Other---$443,709
Other Employee Benefits---$339,348
Other Expenses---$332,206
Occupancy---$215,807
Payroll Taxes---$211,477
Office Expenses---$117,453
Pension Plan Contributions---$112,800
Depreciation Depletion---$92,250
Conferences and Meetings---$82,120
Insurance---$36,076
Total Functional Expenses$0$0$0$10,328,608

Audited Expense Reconciliation

Line ItemAmount
Expenses per Audited Statements$10,328,608
Total Expenses per Audited Statements$10,328,608
Total Expenses per Form 990$10,328,608
Expenses Not Reported on Financial Statements$0
Expenses Not Reported on Form 990$0
International Activity

International Summary

Offices
1
Employees
0
Spending
$2,639,668

International Compliance

Activity in boycott countries
No
Foreign corporation ownership
No
Foreign partnership interest
No
Interest in foreign trust
No
Passive foreign investment company interest
No
Transfers to foreign corporations
No

International Activities

RegionActivityServicesOfficesEmployeesSpending
Europe (including Iceland and Greenland)Program ServicesGeneral Association Management - Schedule Meetings, Member Services, Conference Callsadvocacy, Government and Regulatory Affairs - Annual Conference Planning and Outreach to Stakeholders10$2,587,793
East Asia and the PacificProgram ServicesGENERAL ASSOCIATION MANAGEMENT - SCHEDULE MEETINGS, MEMBER SERVICES, CONFERENCE CALLSADVOCACY, GOVERNMENT AND REGULATORY AFFAIRS - ANNUAL CONFERENCE PLANNING AND OUTREACH TO STAKEHOLDERSNOTE: IN JANUARY 2009 PPTA'S OFFICE IN JAPAN CLOSED AND THE CONTRACT WITH ITS SINGLE EMPLOYEE WAS TERMINATED.00$51,875
Fundraising, Events, and Gaming
Fundraising activities
No
Gaming activities
No
Professional fundraiser used
No

Fundraising and Gaming Totals

Line ItemAmount
Professional Fundraising Fees$0
Political and Lobbying Activity
Political campaign activity
No
In-house lobbying only
No
Subject to proxy tax
Yes

Reported Spending and Taxes

Line ItemAmount
Current Year Nondeductible Lobbying and Political Cost$1,196,584
Total Nondeductible Lobbying and Political Cost$1,179,111
Political Expenditures$0
Section 527 Activity Spending$0
Governance and Compliance

Governance Checklist

Compiled or reviewed by an accountant
No
Annual disclosure for covered persons
Yes
Audit committee
Yes
Backup withholding compliance
Yes
Business relationship with family members
No
Business relationship with organization members
No
Material changes to governing documents
No
Compensation from other sources disclosed
No
CEO compensation reviewed
Yes
Other officer compensation reviewed
Yes
Conflict-of-interest policy
Yes
Audited financial statements prepared
No
Key decisions subject to board approval
No
Management duties delegated
No

Governance Explanations

Form 990, Part VI, Section A, Line 6

“Membership in the plasma protein therapeutics association shall consist of organizations and groups of organizations whose interests support the objectives of the plasma protein therapeutics association and meet specific criteria set forth by the association's bylaws and enforced by the global board of directors. Membership classes shall include: 1. Global membership 2. Regional membership 3. Collector membership 4. Associate membership”

Form 990, Part VI, Section A, Line 7A

“Each member shall be interested in supporting the objectives of the plasma protein therapeutics association and shall be elected to membership as provided in the by-laws. Membership classes shall include: 1. Global membership 2. Regional membership 3. Collector membership 4. Associate membership all applications for membership in the association must be made in writing to the global board of directors (gbd) and must be approved by the gbd. The membership application must contain sufficient information to demonstrate compliance with the appropriate eligibility requirements and in the case of applicants for global membership must include two letters of erecommendation from members of the gbd supportive of the applicant's ethical and business good standing in the plasma products industry. Membership approval requires the affirmative vote of at least two-thirds of the gbd.”

Form 990, Part VI, Section B, Line 11

“Management reviewed the form 990 prior to filing.”

Form 990, Part VI, Section B, Line 12C

“On an annual basis, all officers, directors, key employees, and highest compensated employees are provided a copy of the association's written conflict of interest policy, and are asked to review it as a reminder that all conflicts of interest are to be reported to an officer of the association as soon as possible after the discovery of a potential conflict of interest so that safeguards can be established to protect all parties.”

Form 990, Part VI, Section B, Line 15

“The process for determining the compensation for the ceo & president is during an executive session of the board of directors, the board discussed the general salary and benefit levels of people in similar positions. Surveys and general personal experience of the board were used in deciding the compensation package of the ceo & president. For the top management staff, jan m. Bult (ppta ceo & president) reviews a report of the compensation, including bonuses, with the compensation committee of the board (chairman and treasurer). They discuss the salary levels of the staff and review for reasonableness based on experience with the functions within their own organization as well as personal experience in other non-profit boards that they are a part of.”

Form 990, Part VI, Section C, Line 19

“Ppta makes its form 990 available to those who request. The governing documents and audited financial statements are not generally made available to the general public, but if requests for copies of these documents were to be received, the organization would consider making them available to the requestor.”

Filing and Contact Details

Filer

Filer Name
Plasma Protein Therapeutics Association
EIN
52-1800187
Phone
4434584668
Address
147 OLD SOLOMONS ISLAND RD NO 100, ANNAPOLIS, MD 21401
Doing Business As
Ppta

Signing Officer

Name
Jan M Bult
Title
CEO & President
Phone
4102638296
Signed
2015-11-12
Discuss with paid preparer
Yes

Organization Details

Principal Officer
Jan M Bult
Formed
1992
Legal Domicile
Md
Voting Board Members
5
Independent Board Members
5
Employees
27
Volunteers
0

Preparer

Firm
Tate and Tryon
Address
2021 L STREET NW SUITE 400, WASHINGTON, DC 20036
Preparer
Frederick Longwood
Phone
2022932200
Supplemental Narrative

Additional Explanations

FORM 990, PART XI, LINE 9:

“Gain on foreign currency translation 2,581.”

Form 990, Part XII, Line 2C

“The audit oversight process has remained unchanged from the prior year.”

Financial Statement Notes

PART X, LINE 2:

“The association believes that it has appropriate support for any income tax positions taken. Therefore, management has not identified any uncertain income tax positions. Generally, income tax returns related to the current and three prior years remain open for examination by taxing authorities.”

Raw XML AppendixShowing 400 of 631 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990/AccountantCompileOrReviewInd00
IRS990/AccountsPayableAccrExpnssGrp/BOYAmt01418035
IRS990/AccountsPayableAccrExpnssGrp/EOYAmt01182718
IRS990/AccountsReceivableGrp/BOYAmt0407635
IRS990/AccountsReceivableGrp/EOYAmt0456313
IRS990/ActivitiesConductedPrtshpInd00
IRS990/ActivityOrMissionDesc0PPTA ADVOCATES AND PROMOTES SAFE AND EFFECTIVE PLASMA PROTEIN THERAPEUTICS.
IRS990/AllOtherExpensesGrp/TotalAmt0773307
IRS990/AnnualDisclosureCoveredPrsnInd01
IRS990/AuditCommitteeInd01
IRS990/BackupWthldComplianceInd01
IRS990/BooksInCareOfDetail/BusinessName/BusinessNameLine1Txt0THE ASSOCIATION
IRS990/BooksInCareOfDetail/PhoneNum04434584668
IRS990/BooksInCareOfDetail/USAddress/AddressLine1Txt0147 OLD SOLOMONS ISLAND RD 100
IRS990/BooksInCareOfDetail/USAddress/CityNm0ANNAPOLIS
IRS990/BooksInCareOfDetail/USAddress/StateAbbreviationCd0MD
IRS990/BooksInCareOfDetail/USAddress/ZIPCd021401
IRS990/BusinessRlnWithFamMemInd00
IRS990/BusinessRlnWithOfficerEntInd00
IRS990/BusinessRlnWithOrgMemInd00
IRS990/ChangeToOrgDocumentsInd00
IRS990/CntrctRcvdGreaterThan100KCnt01
IRS990/CollectionsOfArtInd00
IRS990/CompCurrentOfcrDirectorsGrp/TotalAmt01588393
IRS990/CompensationFromOtherSrcsInd00
IRS990/CompensationProcessCEOInd01
IRS990/CompensationProcessOtherInd01
IRS990/ConferencesMeetingsGrp/TotalAmt082120
IRS990/ConflictOfInterestPolicyInd01
IRS990/ConservationEasementsInd00
IRS990/ConsolidatedAuditFinclStmtInd00
IRS990/ContractorCompensationGrp/CompensationAmt0379000
IRS990/ContractorCompensationGrp/ContractorAddress/ForeignAddress/AddressLine1Txt019 INVESTIGATOR STREET
IRS990/ContractorCompensationGrp/ContractorAddress/ForeignAddress/CityNm0RED HILL
IRS990/ContractorCompensationGrp/ContractorAddress/ForeignAddress/CountryCd0AU
IRS990/ContractorCompensationGrp/ContractorAddress/ForeignAddress/ForeignPostalCd02603
IRS990/ContractorCompensationGrp/ContractorAddress/ForeignAddress/ProvinceOrStateNm0ACT
IRS990/ContractorCompensationGrp/ContractorName/BusinessName/BusinessNameLine1Txt0ALMAR THERAPEUTICS PTY LTD
IRS990/ContractorCompensationGrp/ServicesDesc0CONSULTING
IRS990/CreditCounselingInd00
IRS990/CYBenefitsPaidToMembersAmt00
IRS990/CYContributionsGrantsAmt00
IRS990/CYGrantsAndSimilarPaidAmt00
IRS990/CYInvestmentIncomeAmt02505
IRS990/CYOtherExpensesAmt06142864
IRS990/CYOtherRevenueAmt011216
IRS990/CYProgramServiceRevenueAmt010655237
IRS990/CYRevenuesLessExpensesAmt0340350
IRS990/CYSalariesCompEmpBnftPaidAmt04185744
IRS990/CYTotalExpensesAmt010328608
IRS990/CYTotalFundraisingExpenseAmt00
IRS990/CYTotalProfFndrsngExpnsAmt00
IRS990/CYTotalRevenueAmt010668958
IRS990/DecisionsSubjectToApprovaInd00
IRS990/DeductibleArtContributionInd00
IRS990/DeductibleNonCashContriInd00
IRS990/DeferredRevenueGrp/BOYAmt0710775
IRS990/DeferredRevenueGrp/EOYAmt01082027
IRS990/DelegationOfMgmtDutiesInd00
IRS990/DepreciationDepletionGrp/TotalAmt092250
IRS990/Desc0PPTA REPRESENTS THE INTERESTS OF THE PLASMA COLLECTION AND FRACTIONATION INDUSTRY WITH REGARD TO REGULATORY, LEGISLATIVE AND OTHER PUBLIC POLICY ISSUES. PPTA STAFF WORKS COOPERATIVELY WITH GOVERNMENTAL INSTITUTIONS AND REGULATORY AGENCIES THROUGHOUT THE WORLD. PPTA STAFF MONITOR REGULATORY AND POLICY ACTIVITIES (UNITED STATES CONGRESS, THE EUROPEAN COMMISSION, THE WORLD HEALTH ORGANIZATION, FDA, EMEA AND VARIOUS OTHER INTERNATIONAL AND NATIONAL REGULATORY AGENCIES AND COMMITTEES), COORDINATE INDUSTRY POSITIONS ON EXISTING, NEW AND EMERGING ISSUES, AND DEFINE AND DEVELOP STRATEGIC INITIATIVES THAT ENHANCE THE INDUSTRY'S REGULATORY ENVIRONMENT.PPTA SPEAKS WITH ONE VOICE ON ASSOCIATION AND MEMBER PROGRAMS AND INITIATIVES.PLASMA COLLECTION:PLASMAPHERESIS IS ONE OF THE MAIN WAYS TO OBTAIN PLASMA, ANOTHER TYPE OF PLASMA IS "RECOVERED PLASMA." THROUGH PLASMAPHERESIS, ONLY THE PLASMA IS COLLECTED AND THE BLOOD CELLS REMAIN IN THE DONOR. BLOOD DONORS LOSE PART OF THE OXYGEN-CARRYING CAPACITY OF THE BLOOD, WHICH IS RESTORED RELATIVELY SLOWLY. PLASMA DONORS ONLY LOSE THE PROTEINS IN PLASMA AND RETAIN THEIR CAPACITY FOR OXYGEN TRANSPORT. SINCE PLASMA PROTEINS ARE SYNTHESIZED MORE RAPIDLY THAN BLOOD CELLS, IT IS POSSIBLE TO COLLECT A LARGER VOLUME ON EACH OCCASION AND COLLECT FROM A DONOR MORE OFTEN. IN MOST CASES, BLOOD ESTABLISHMENTS HAVE ACQUIRED PLASMAPHERESIS EQUIPMENT AND DELIVER SOURCE PLASMA (APHERESIS PLASMA) DIRECTLY TO FRACTIONATORS.PLASMA COLLECTION CENTERS ARE REGULATED BY THE COUNTRY IN WHICH THEY ARE LOCATED, AS WELL AS THE COUNTRIES TO WHICH THEY MAY SUPPLY PLASMA FOR FURTHER MANUFACTURE. PLASMA COLLECTION IN THE US:MOST PLASMA CENTERS ARE LOCATED IN THE UNITED STATES AND THEREFORE, ARE LICENSED AND REGULATED BY THE FOOD & DRUG ADMINISTRATION (FDA). THESE PLASMA CENTERS ARE INSPECTED ON AN UNANNOUNCED BASIS AND MUST COMPLY WITH STRICT FDA REGULATIONS FOR DONOR SAFETY AND PRODUCT QUALITY. THEY MUST ALSO COMPLY WITH LABORATORY TESTING REGULATIONS UNDER THE US CLINICAL LABORATORY IMPROVEMENT ACT (CLIA) AND WORKER SAFETY REGULATIONS UNDER THE OCCUPATIONAL SAFETY AND HEALTH ACT (OSHA).VOLUNTARY STANDARDS:IN ADDITION TO GOVERNMENT-MANDATED REGULATIONS, THE PLASMA INDUSTRY ADHERES TO VOLUNTARY STANDARDS SET BY INDUSTRY, THE PPTA INTERNATIONAL QUALITY PLASMA PROGRAM (IQPP). THIS PROGRAM WAS ESTABLISHED BY PPTA SOURCE (FORMERLY ABRA) IN 1991. IQPP CERTIFICATION REFLECTS THE QUALITY OF A FACILITY'S DONORS AND THE PLASMA COLLECTED, THE PROFESSIONAL/MEDICAL OPERATION OF THE FACILITY AND A WELL-TRAINED STAFF. PPTA SOURCE ALSO DEVELOPED THE NATIONAL DONOR DEFERRAL REGISTRY (NDDR) IN THE US WHICH IS DESIGNED TO BE USED BY PLASMA CENTERS TO CHECK DONORS AGAINST A COMPUTERIZED LIST OF PERMANENTLY DEFERRED DONORS. THIS SYSTEM SERVES TO FURTHER ASSURE THE SAFETY OF PLASMA AND PLASMA PRODUCTS. PLASMA FRACTIONATION:ONCE THE SOURCE PLASMA IS COLLECTED, PPTA MEMBERS USE THE PLASMA TO PRODUCE LIFE-SAVING THERAPIES. THERAPIES INCLUDE ALBUMIN, USED AS A BLOOD VOLUME EXPANDER; COAGULATION THERAPEUTIES, USED IN THE TREATMENT OF VARIOUS BLEEDING DISORDERS; IMMUNE GLOBULIN THERAPEUTICS FOR INFECTIOUS DISEASE PREVENTION, AND ALPHA-1 PROTEINASE INHIBITOR, USED IN THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY. THE ENVIRONMENTS IN WHICH THESE THERAPIES ARE MADE ARE TIGHTLY REGULATED. INTERNATIONALLY, THE EUROPEAN COMMISSION, THE COUNCIL OF EUROPE, THE WORLD HEALTH ORGANIZATION AND HEALTH AUTHORITIES WITHIN INDIVIDUAL NATIONS THROUGHOUT EUROPE AND THE PACIFIC RIM PARTICIPATE IN THE REGULATION OF THE INTERNATIONAL PLASMA DERIVATIVES INDUSTRY. IN THE UNITED STATES, THE FOOD AND DRUG ADMINISTRATION, THE NATIONAL INSTITUTES OF HEALTH, THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION (OSHA), THE DEPARTMENT OF TRANSPORTATION, AND CONGRESS ALL MAINTAIN AND PRACTICE REGULATORY OVERSIGHT.IN ADDITION TO GOVERNMENT MANDATED REGULATIONS, PPTA MEMBERS ADHERE TO THE PPTA-DEVELOPED QUALITY, SAFETY, EXCELLENCE, ASSURANCE
IRS990/DescribedInSection501c3Ind00
IRS990/DisregardedEntityInd00
IRS990/DocumentRetentionPolicyInd01
IRS990/DoingBusinessAsName/BusinessNameLine1Txt0PPTA
IRS990/DonorAdvisedFundInd00
IRS990/ElectionOfBoardMembersInd01
IRS990/EmployeeCnt027
IRS990/EmploymentTaxReturnsFiledInd01
IRS990/FamilyOrBusinessRlnInd00
IRS990/FederalGrantAuditRequiredInd00
IRS990/FeesForServicesOtherGrp/TotalAmt0443709
IRS990/ForeignActivitiesInd01
IRS990/ForeignCountryCd0BE
IRS990/ForeignFinancialAccountInd01
IRS990/ForeignOfficeInd01
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt01.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt11.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt21.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt31.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt41.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt51.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt640.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt740.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt840.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt940.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt1040.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt1140.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt1240.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt1340.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt1440.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt1532.00
IRS990/Form990PartVIISectionAGrp/HighestCompensatedEmployeeInd0X
IRS990/Form990PartVIISectionAGrp/HighestCompensatedEmployeeInd1X
IRS990/Form990PartVIISectionAGrp/HighestCompensatedEmployeeInd2X
IRS990/Form990PartVIISectionAGrp/HighestCompensatedEmployeeInd3X
IRS990/Form990PartVIISectionAGrp/HighestCompensatedEmployeeInd4X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd0X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd1X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd2X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd3X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd4X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd5X
IRS990/Form990PartVIISectionAGrp/KeyEmployeeInd0X
IRS990/Form990PartVIISectionAGrp/KeyEmployeeInd1X
IRS990/Form990PartVIISectionAGrp/KeyEmployeeInd2X
IRS990/Form990PartVIISectionAGrp/OfficerInd0X
IRS990/Form990PartVIISectionAGrp/OfficerInd1X
IRS990/Form990PartVIISectionAGrp/OfficerInd2X
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt00
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt10
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt20
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt30
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt40
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt50
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt645956
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt722812
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt828454
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt926225
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt1044198
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt1136413
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt1244060
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt135446
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt1432978
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt1537377
IRS990/Form990PartVIISectionAGrp/PersonNm0PAOLO MARCUCCI
IRS990/Form990PartVIISectionAGrp/PersonNm1RONALD LLOYD
IRS990/Form990PartVIISectionAGrp/PersonNm2GREGOR SCHULZ
IRS990/Form990PartVIISectionAGrp/PersonNm3KAREN ETCHBERGER
IRS990/Form990PartVIISectionAGrp/PersonNm4DAVID BELL
IRS990/Form990PartVIISectionAGrp/PersonNm5PAUL ROSENTHAL ESQ
IRS990/Form990PartVIISectionAGrp/PersonNm6JAN M BULT
IRS990/Form990PartVIISectionAGrp/PersonNm7GENE STROSHANE
IRS990/Form990PartVIISectionAGrp/PersonNm8JULIE BIRKOFER
IRS990/Form990PartVIISectionAGrp/PersonNm9JOSHUA PENROD
IRS990/Form990PartVIISectionAGrp/PersonNm10JOHN DELACOURT
IRS990/Form990PartVIISectionAGrp/PersonNm11MARY GUSTAFSON
IRS990/Form990PartVIISectionAGrp/PersonNm12WILLIAM SPEIR
IRS990/Form990PartVIISectionAGrp/PersonNm13JOHN CROSLAND III
IRS990/Form990PartVIISectionAGrp/PersonNm14MIKE MCCORMICK
IRS990/Form990PartVIISectionAGrp/PersonNm15GEORGE SCHREIBER
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt00
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt10
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt20
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt30
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt40
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt50
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt6435596
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt7143072
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt8323526
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt9238945
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt10260051
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt11275733
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt12175450
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt13103761
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt14120944
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt15189103
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt00
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt10
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt20
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt30
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt40
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt50
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt60
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt70
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt80
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt90
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt100
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt110
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt120
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt130
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt140
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt150
IRS990/Form990PartVIISectionAGrp/TitleTxt0GLOBAL BOARD CHAIRMAN
IRS990/Form990PartVIISectionAGrp/TitleTxt1GLOBAL BOARD MEMBER
IRS990/Form990PartVIISectionAGrp/TitleTxt2TREASURER
IRS990/Form990PartVIISectionAGrp/TitleTxt3GLOBAL BOARD MEMBER
IRS990/Form990PartVIISectionAGrp/TitleTxt4GLOBAL BOARD MEMBER
IRS990/Form990PartVIISectionAGrp/TitleTxt5GLOBAL BOARD MEMBER
IRS990/Form990PartVIISectionAGrp/TitleTxt6PRESIDENT & CEO
IRS990/Form990PartVIISectionAGrp/TitleTxt7CONTROLLER
IRS990/Form990PartVIISectionAGrp/TitleTxt8SENIOR VP, NORTH AMERICA
IRS990/Form990PartVIISectionAGrp/TitleTxt9VP, SOURCE
IRS990/Form990PartVIISectionAGrp/TitleTxt10VP, LEGAL AFFAIRS
IRS990/Form990PartVIISectionAGrp/TitleTxt11VP, REGULATORY POLICY
IRS990/Form990PartVIISectionAGrp/TitleTxt12SENIOR DIRECTOR, STATE AFFAIRS
IRS990/Form990PartVIISectionAGrp/TitleTxt13JOHN CROSLAND III
IRS990/Form990PartVIISectionAGrp/TitleTxt14MIKE MCCORMICK
IRS990/Form990PartVIISectionAGrp/TitleTxt15GEORGE SCHREIBER
IRS990/Form990ProvidedToGvrnBodyInd00
IRS990/Form990TFiledInd01
IRS990/FormationYr01992
IRS990/FormerOfcrEmployeesListedInd00
IRS990/FSAuditedBasisGrp/SeparateBasisFinclStmtInd0X
IRS990/FSAuditedInd01
IRS990/FundraisingActivitiesInd00
IRS990/GamingActivitiesInd00
IRS990/GoverningBodyVotingMembersCnt05
IRS990/GrantsToIndividualsInd00
IRS990/GrantsToOrganizationsInd00
IRS990/GrantToRelatedPersonInd00
IRS990/GrossReceiptsAmt010668958
IRS990/GroupReturnForAffiliatesInd00
IRS990/IncludeFIN48FootnoteInd01
IRS990/IndependentAuditFinclStmtInd01
IRS990/IndependentVotingMemberCnt05
IRS990/IndivRcvdGreaterThan100KCnt010
IRS990/IndoorTanningServicesInd00
IRS990/InfoInScheduleOPartIIIInd0X
IRS990/InfoInScheduleOPartVIInd0X
IRS990/InfoInScheduleOPartXIIInd0X
IRS990/InfoInScheduleOPartXIInd0X
IRS990/InsuranceGrp/TotalAmt036076
IRS990/InvestmentIncomeGrp/ExclusionAmt02505
IRS990/InvestmentIncomeGrp/TotalRevenueColumnAmt02505
IRS990/InvestmentInJointVentureInd00
IRS990/IRPDocumentCnt05
IRS990/IRPDocumentW2GCnt00
IRS990/LandBldgEquipAccumDeprecAmt01232317
IRS990/LandBldgEquipBasisNetGrp/BOYAmt0148031
IRS990/LandBldgEquipBasisNetGrp/EOYAmt0280780
IRS990/LandBldgEquipCostOrOtherBssAmt01513097
IRS990/LegalDomicileStateCd0MD
IRS990/LoanOutstandingInd00
IRS990/LocalChaptersInd00
IRS990/MaterialDiversionOrMisuseInd00
IRS990/MembersOrStockholdersInd01
IRS990/MethodOfAccountingAccrualInd0X
IRS990/MinutesOfCommitteesInd01
IRS990/MinutesOfGoverningBodyInd01
IRS990/MissionDesc0THE PLASMA PROTEIN THERAPEUTICS ASSOCIATION SERVES AS THE CORNERSTONE FOR CONSENSUS DEVELOPMENT OF INDUSTRY-WIDE INITIATIVES AND IS THE PRIMARY ADVOCATE FOR THE LEADING PRODUCERS OF PLASMA-BASED AND RELATED RECOMBINANT BIOLOGICAL THERAPEUTICS. THE ASSOCIATION'S MISSION IS TO PROMOTE AN ENVIRONMENT THAT FOSTERS THE AVAILABILITY OF SAFE AND EFFECTIVE PLASMA PROTEIN THERAPEUTICS. AS THE GLOBAL REPRESENTATIVE FOR THE PLASMA THERAPEUTICS INDUSTRY, THE ASSOCIATION WORKS COOPERATIVELY WITH PATIENT GROUPS, LEGISLATORS, REGULATORY AGENCIES AND OTHERS TO ADDRESS CRITICAL ISSUES THAT IMPACT THE INDUSTRY AND THOSE PEOPLE WHO DEPEND ON PLASMA PROTEIN THERAPEUTICS. THE ASSOCIATION'S GLOBAL COMMITTEES AND REGIONAL WORKING GROUPS BRING TOGETHER INDUSTRY EXPERTS TO FOCUS ON IMPORTANT ISSUES RELATING TO THE QUALITY, SAFETY AND EFFICACY OF PLASMA THERAPEUTICS.
IRS990/MoreThan5000KToIndividualsInd00
IRS990/MoreThan5000KToOrgInd00
IRS990/NetAssetsOrFundBalancesBOYAmt02823027
IRS990/NetAssetsOrFundBalancesEOYAmt03165958
IRS990/NetUnrelatedBusTxblIncmAmt00
IRS990/NondeductibleContributionsInd01
IRS990/NondeductibleContriDisclInd01
IRS990/OccupancyGrp/TotalAmt0215807
IRS990/OfficeExpensesGrp/TotalAmt0117453
IRS990/OfficerMailingAddressInd00
IRS990/OperateHospitalInd00
IRS990/Organization501cInd0X
IRS990/OrganizationFollowsSFAS117Ind0X
IRS990/OtherChangesInNetAssetsAmt02581
IRS990/OtherEmployeeBenefitsGrp/TotalAmt0339348
IRS990/OtherExpensesGrp/Desc0PPTA-EUROPE
IRS990/OtherExpensesGrp/Desc1ASSOCIATION PROJECTS
IRS990/OtherExpensesGrp/Desc2MISCELLANEOUS
IRS990/OtherExpensesGrp/Desc3CERTIFICATION
IRS990/OtherExpensesGrp/TotalAmt02587793
IRS990/OtherExpensesGrp/TotalAmt1549422
IRS990/OtherExpensesGrp/TotalAmt2450185
IRS990/OtherExpensesGrp/TotalAmt3332206
IRS990/OtherLiabilitiesGrp/BOYAmt0144322
IRS990/OtherLiabilitiesGrp/EOYAmt00
IRS990/OtherRevenueMiscGrp/BusinessCd0900099
IRS990/OtherRevenueMiscGrp/Desc0INSURANCE REIMBURSEMENT
IRS990/OtherRevenueMiscGrp/ExclusionAmt011216
IRS990/OtherRevenueMiscGrp/TotalRevenueColumnAmt011216
IRS990/OtherRevenueTotalAmt011216
IRS990/OtherSalariesAndWagesGrp/TotalAmt01933726
IRS990/PartialLiquidationInd00
IRS990/PayrollTaxesGrp/TotalAmt0211477
IRS990/PensionPlanContributionsGrp/TotalAmt0112800
IRS990/PoliticalCampaignActyInd00
IRS990/PrepaidExpensesDefrdChargesGrp/BOYAmt085619
IRS990/PrepaidExpensesDefrdChargesGrp/EOYAmt087782
IRS990/PrincipalOfficerNm0JAN M BULT
IRS990/ProfessionalFundraisingInd00
IRS990/ProgramServiceRevenueGrp/BusinessCd0900099
IRS990/ProgramServiceRevenueGrp/BusinessCd1900099
IRS990/ProgramServiceRevenueGrp/BusinessCd2900099
IRS990/ProgramServiceRevenueGrp/BusinessCd3900099
IRS990/ProgramServiceRevenueGrp/BusinessCd4900099
IRS990/ProgramServiceRevenueGrp/Desc0MEMBER DUES
IRS990/ProgramServiceRevenueGrp/Desc1NDDR
IRS990/ProgramServiceRevenueGrp/Desc2CERTIFICATION
IRS990/ProgramServiceRevenueGrp/Desc3FORUMS
IRS990/ProgramServiceRevenueGrp/Desc4OTHER
IRS990/ProgramServiceRevenueGrp/RelatedOrExemptFuncIncomeAmt06888400
IRS990/ProgramServiceRevenueGrp/RelatedOrExemptFuncIncomeAmt12325140
IRS990/ProgramServiceRevenueGrp/RelatedOrExemptFuncIncomeAmt2625665
IRS990/ProgramServiceRevenueGrp/RelatedOrExemptFuncIncomeAmt3336794
IRS990/ProgramServiceRevenueGrp/RelatedOrExemptFuncIncomeAmt4200000
IRS990/ProgramServiceRevenueGrp/TotalRevenueColumnAmt06888400
IRS990/ProgramServiceRevenueGrp/TotalRevenueColumnAmt12325140
IRS990/ProgramServiceRevenueGrp/TotalRevenueColumnAmt2625665
IRS990/ProgramServiceRevenueGrp/TotalRevenueColumnAmt3336794
IRS990/ProgramServiceRevenueGrp/TotalRevenueColumnAmt4240870
IRS990/ProgramServiceRevenueGrp/UnrelatedBusinessRevenueAmt040870
IRS990/ProgSrvcAccomActy2Grp/Desc0FOUNDED IN 1994, PPTA EUROPE, FORMERLY THE EUROPEAN ASSOCIATION OF THE PLASMA PRODUCTS INDUSTRY (EAPPI), IS THE PRIMARY ADVOCATE FOR THE LEADING PRODUCERS OF PLASMA-BASED AND RELATED RECOMBINANT BIOLOGICAL THERAPEUTICS. THE ASSOCIATION, THROUGH ITS WORKING GROUPS, DEVELOPS INDUSTRY-WIDE CONSENSUS POSITIONS AND INITIATIVES.PPTA EUROPE ACTS AS THE PRINCIPLE INTERLOCUTOR WITH REGULATORY AUTHORITIES ON A NATIONAL AND EUROPEAN LEVEL AND WITH NATIONAL GOVERNMENTS. PPTA EUROPE IS COMMITTED TO BEING INVOLVED IN ALL DISCUSSIONS DIRECTLY RELEVANT TO THE PLASMA THERAPEUTICS INDUSTRY AND THE PATIENTS WHO DEPEND ON THE MEDICINES PRODUCED BY OUR MEMBERS.PPTA EUROPE WORKS CLOSELY WITH PPTA NORTH AMERICA TO BRING TOGETHER INDUSTRY EXPERTS FROM AROUND THE WORLD TO FOCUS ON IMPORTANT ISSUES RELATING TO THE QUALITY, SAFETY AND EFFICACY OF PLASMA THERAPEUTICS.
IRS990/ProgSrvcAccomActy3Grp/Desc0PATIENT NOTIFICATION SYSTEM:THE PATIENT NOTIFICATION SYSTEM IS A FREE, CONFIDENTIAL, 24-HOUR COMMUNICATION SYSTEM PROVIDING INFORMATION ON PLASMA-DERIVED AND RECOMBINANT PRODUCT WITHDRAWALS AND RECALLS IN NORTH AMERICA.THE SYSTEM WAS CREATED TO PROVIDE CONSUMERS WITH A SINGLE, CONVENIENT AND CONFIDENTIAL SOURCE FOR UP-TO-DATE PRODUCT WITHDRAWAL AND RECALL INFORMATION. LED BY THE PLASMA PROTEIN THERAPEUTICS ASSOCIATION (PPTA), THE PATIENT NOTIFICATION SYSTEM WAS DEVELOPED BY THE PRODUCERS AND DISTRIBUTORS OF PLASMA PRODUCTS WITH DIRECT INPUT FROM CONSUMERS.ORIGINALLY AVAILABLE IN THE US, IN 2002, THE SYSTEM EXTENDED TO CONSUMERS IN CANADA. IN EUROPE, IT IS THE RESPONSIBILITY OF THE NATIONAL GOVERNMENTS TO INFORM CONSUMERS ABOUT PRODUCT WITHDRAWAL AND RECALL INFORMATION. ON THIS BASIS PPTA EUROPE DOES NOT HAVE A PATIENT NOTIFICATION SYSTEM IN OPERATION.ENSURING CONFIDENTIALITY:MAINTAINING PATIENT CONFIDENTIALITY WAS ONE OF THE PRIMARY CONSIDERATIONS IN DEVELOPING THE SYSTEM. AN ADVISORY PANEL MADE UP OF REPRESENTATIVES FROM CONSUMER GROUPS HELPED DESIGN THE SYSTEM TO SAFEGUARD SENSITIVE PATIENT INFORMATION. TO ENSURE CONFIDENTIALITY, THE PATIENT NOTIFICATION SYSTEM IS OPERATED BY STERICYCLE, INC., AN INDEPENDENT ORGANIZATION THAT SPECIALIZES IN PHARMACEUTICAL NOTIFICATIONS.ALL PATIENT INFORMATION WILL BE HELD IN STRICT CONFIDENCE BY THE NATIONAL NOTIFICATION CENTER.FREE TO CONSUMERS:THERE IS NO FEE TO PARTICIPATE IN THE PATIENT NOTIFICATION SYSTEM. THE SYSTEM IS FUNDED BY THE PRODUCERS AND DISTRIBUTORS OF PLASMA-DERIVED AND RECOMBINANT PRODUCTS AND IS FREE TO CONSUMERS AND HEALTH CARE PROVIDERS.COOPERATIVE EFFORT BETWEEN INDUSTRY AND CONSUMERS:KEY CONSUMER GROUPS, INCLUDING ALPHA 1 ASSOCIATION, ALPHA ONE FOUNDATION, COMMITTEE OF TEN THOUSAND, HEMOPHILIA FEDERATION OF AMERICA, IMMUNE DEFICIENCY FOUNDATION AND NATIONAL HEMOPHILIA FOUNDATION, WORKED CLOSELY WITH THE PLASMA PROTEIN THERAPEUTICS INDUSTRY IN DESIGNING THE PATIENT NOTIFICATION SYSTEM. THE SYSTEM IS ADMINISTERED BY PPTA AND IS SUPPORTED AND FUNDED BY ALL MAJOR PLASMA-DERIVED AND RECOMBINANT MANUFACTURERS. A WORKING GROUP MADE UP OF STAKEHOLDERS AND INDUSTRY REPRESENTATIVES HAS BEEN FORMED TO PROVIDE INPUT ON THE SYSTEM AND MAKE ADDITIONAL RECOMMENDATIONS FOR FUTURE ENHANCEMENTS.HOW THE SYSTEM WORKS:FIRST, ANYONE INTERESTED IN PARTICIPATING REGISTERS WITH THE PATIENT NOTIFICATION SYSTEM AND PROVIDES GENERAL CONTACT INFORMATION, INCLUDING THEIR PREFERRED METHOD OF NOTIFICATION. PARTICIPANTS HAVE THE OPTION OF BEING NOTIFIED BY TELEPHONE, FAX, OR E-MAIL, WHICHEVER IS MOST CONVENIENT FOR THEM. IF A PRODUCT IS WITHDRAWN OR RECALLED, THE COMPANY INVOLVED IMMEDIATELY CONTACTS THE STERICYCLE, INC. WHO THEN NOTIFIES THE ENROLLED REGISTRANT DIRECTLY. EVERY EFFORT WILL BE MADE TO NOTIFY REGISTRANTS WITHIN 24 HOURS. THOSE REGISTRANTS WHO CHOOSE TO BE NOTIFIED BY TELEPHONE, FAX OR E-MAIL WILL ALSO RECEIVE A LETTER BY FIRST-CLASS MAIL TO ENSURE RECEIPT OF THE INFORMATION. IN ADDITION, CONSUMERS CAN CALL A 24-HOUR, TOLL-FREE NUMBER (1-888-UPDATE-U) FOR CURRENT INFORMATION ON PRODUCT RECALLS OR WITHDRAWALS. TO MAXIMIZE THE USEFULNESS OF THE SYSTEM, IT IS IMPORTANT FOR CONSUMERS TO KEEP ACCURATE INFUSION LOGS AND RECORD THE LOT NUMBER, PRODUCT NAME AND MANUFACTURER FOR ALL PLASMA PRODUCTS USED.HOW TO REGISTER:PARTICIPANTS CAN REGISTER ON LINE AT: WWW.PATIENTNOTIFICATIONSYSTEM.ORG OR BY CALLING 1-888-UPDATE-U.WORKING GROUPCONSUMER GROUPS:ALPHA-1 ASSOCIATIONALPHA 1 FOUNDATIONCOMMITTEE OF TEN THOUSANDHEMOPHILIA FEDERATION OF AMERICAIMMUNE DEFICIENCY FOUNDATIONNATIONAL HEMOPHILIA FOUNDATIONGUILLAN-BARRE/CIDP FOUNDATIONPLASMA PRODUCT PRODUCERS AND DISTRIBUTORS:CSL BEHRINGBAXTER BIOSCIENCEBAYER HEALTHCARE LLCGRIFOLS USA LLCWYETH PHARMACEUTICALS/NOW PFIZER INC.NOVO NORDISK, INC.TALECRIS BIOTHERAPEUTICS OCTAPHARMA USA, INC.CANGENE CORP.SYSTEM ADMINISTRATOR:PLASMA PROTEIN THERAPEUTICS ASSOCIATION147 OLD SOLOMON'S ISLAND RD., STE. 100ANNAPOLIS MD 21401PHONE: (202) 789-3100FAX: (410) 263-2298WWW.P
IRS990/ProgSrvcAccomActyOtherGrp/Desc0SYSTEM FOR REPORTING MONTHLY SUPPLYAND AVAILABILITY DATAIN RESPONSE TO PUBLIC HEALTH-RELATED CONCERNS REGARDING PRODUCT SHORTAGES, PPTA NORTH AMERICA BEGAN COLLECTING AND PUBLISHING DATA ON THE DISTRIBUTION OF IMMUNE GLOBULIN, HIGH PURITY FACTOR VIII, RECOMBINANT FACTOR VIII, AND ALBUMIN. THIS INFORMATION HAS BEEN PUBLISHED ON A MONTHLY BASIS SINCE 1998, IN COMPLIANCE WITH THE SPECIFIC RECOMMENDATION OF THE ADVISORY COMMITTEE ON BLOOD SAFETY AND AVAILABILITY, AS WELL AS THE EXPECTATIONS OF FDA, HHS, PATIENTS, PHYSICIANS, AND OTHER STAKEHOLDERS.
IRS990/ProgSrvcAccomActyOtherGrp/Desc1QUALITY & SAFETY THE PLASMA PROTEIN THERAPEUTICS ASSOCIATION AND THE INDUSTRY IT REPRESENTS, TAKE VERY SERIOUSLY THE QUALITY AND SAFETY OF THE PRODUCTS AND THE HEALTH OF THE PEOPLE WHO USE THESE LIFESAVING THERAPIES.AS A STANDARD-BEARER FOR THE INDUSTRY, PPTA HAS ESTABLISHED SEVERAL DIFFERENT QUALITY PROGRAMS TO PROMOTE QUALITY PRACTICES FROM VEIN TO VEIN, FROM DONOR TO PATIENT. THESE TWO PROGRAMS, THE INTERNATIONAL QUALITY PLASMA PROGRAM (IQPP) AND QSEAL (QUALITY STANDARDS OF EXCELLENCE, ASSURANCE AND LEADERSHIP) HAVE PROPELLED MEMBERS OF PPTA TO THE TOP OF THE BIOPHARMACEUTICAL INDUSTRY. THE STANDARDS WITHIN THESE TWO PROGRAMS COVER ALL AREAS THAT INFLUENCE THE QUALITY AND SAFETY OF SOURCE PLASMA - FROM COLLECTION TO TRANSPORTATION AND FROM STORAGE TO MANUFACTURING. THESE QUALITY PROGRAMS ARE DESIGNED TO SHAPE FUTURE NEEDS AND REQUIREMENTS AND TO ANTICIPATE THE RESOURCES NECESSARY TO ACCOMMODATE THEM. NEW VOLUNTARY STANDARD FOR INTERMEDIATES:PPTA HAS FINALIZED THE VOLUNTARY STANDARD FOR INTERMEDIATES. THE PURPOSE OF THIS STANDARD IS TO HAVE A COMMON UNDERSTANDING ABOUT THE ACCEPTANCE OF INTERMEDIATES IN THE MANUFACTURE OF PLASMA DERIVED THERAPIES. THIS STANDARD WILL CONTRIBUTE TO THE COMMITMENT OF PPTA MEMBERS TO PROVIDE THERAPIES OF THE HIGHEST QUALITY. THE STANDARD WAS REVISED TO ADDRESS IMPLEMENTATION DATES FOR INTERMEDIATES MADE FROM RECOVERED PLASMA. THE IMPLEMENTATION DATE FOR THE INTERMEDIATES STANDARD FOR INTERMEDIATES MADE FROM SOURCE PLASMA IS JULY 1, 2003.TECHNICAL CONSIDERATIONS FOR THE PERFORMANCE OF NUCLEIC ACID AMPLIFICATION TECHNOLOGY:THIS GUIDANCE HAS BEEN INCORPORATED INTO THE QSEAL AUDIT FOR ADHERENCE TO PPTA'S VOLUNTARY INDUSTRY STANDARD OF NAT TESTING FOR HIV, HBV, HCV AND PARVOVIRUS B19. QSEAL:PEOPLE AROUND THE WORLD DEPEND ON THERAPEUTICS DERIVED FROM HUMAN PLASMA TO TREAT CONDITIONS SUCH AS HEMOPHILIA, IMMUNE DISORDERS, AND OTHER DISEASES OR INJURIES. SAFETY OF PLASMA THERAPEUTICS IS THE TOP PRIORITY OF THE PLASMA FRACTIONATION INDUSTRY. THE PLASMA PROTEIN THERAPEUTICS ASSOCIATION (PPTA), ON BEHALF OF ITS INDUSTRY MEMBERS, SUPPORTS EFFORTS BY REGULATORY BODIES TO ESTABLISH MINIMUM REQUIREMENTS TO ENSURE THE SAFETY OF THESE PRODUCTS.IN 1996, PPTA ADOPTED FOUR VOLUNTARY STANDARDS WHICH GO BEYOND REGULATORY REQUIREMENTS AND HELP DEFINE THE REGULATIONS AS THEY APPLY TO FRACTIONATION OF PLASMA FOR PLASMA THERAPEUTICS. THESE VOLUNTARY STANDARDS RELATE TO COLLECTING, PROCESSING, AND TESTING OF SOURCE PLASMA BY MEMBER FRACTIONATORS.IN 2000, PPTA ESTABLISHED THE QSEAL CERTIFICATION PROGRAM TO PROVIDE INDEPENDENT CERTIFICATION OF ADHERENCE BY FRACTIONATORS TO THE VOLUNTARY STANDARDS.IN 2001, THE FIRST FIVE PPTA MEMBERS TO RECEIVE THEIR CERTIFICATION WERE RECOGNIZED:ALPHA THERAPEUTIC BAYER BAXTER BIOSCIENCE BIOTEST AVENTIS BEHRING
IRS990/ProhibitedTaxShelterTransInd00
IRS990/PYBenefitsPaidToMembersAmt00
IRS990/PYContributionsGrantsAmt00
IRS990/PYGrantsAndSimilarPaidAmt00
IRS990/PYInvestmentIncomeAmt04260
IRS990/PYOtherExpensesAmt06269742
IRS990/PYOtherRevenueAmt0245006
IRS990/PYProgramServiceRevenueAmt010191385
IRS990/PYRevenuesLessExpensesAmt0-526771
IRS990/PYSalariesCompEmpBnftPaidAmt04697680
IRS990/PYTotalExpensesAmt010967422
IRS990/PYTotalProfFndrsngExpnsAmt00
IRS990/PYTotalRevenueAmt010440651
IRS990/ReconcilationRevenueExpnssAmt0340350
IRS990/RegularMonitoringEnfrcInd01
IRS990/RelatedEntityInd00
IRS990/RelatedOrganizationCtrlEntInd00
IRS990/ReportInvestmentsOtherSecInd00
IRS990/ReportLandBuildingEquipmentInd01
IRS990/ReportOtherAssetsInd00
IRS990/ReportOtherLiabilitiesInd00
IRS990/ReportProgramRelatedInvstInd00
IRS990/SavingsAndTempCashInvstGrp/BOYAmt04454874
IRS990/SavingsAndTempCashInvstGrp/EOYAmt04605828
IRS990/ScheduleBRequiredInd00
IRS990ScheduleC/AggregateReportedDuesNtcAmt01069368
IRS990ScheduleC/AgreeCarryoverPriorYearInd01
IRS990ScheduleC/CarriedOverAmt0109743
IRS990ScheduleC/DuesAssessmentsAmt06888400
IRS990ScheduleC/Expended527ActivitiesAmt00
IRS990ScheduleC/InternalFundsContributedAmt00
IRS990ScheduleC/NonDedLbbyngPltclCyovAmt0-17473
IRS990ScheduleC/NonDeductibleLbbyngPltclCYAmt01196584
IRS990ScheduleC/NonDeductibleLbbyngPltclTotAmt01179111
IRS990ScheduleC/OnlyInHouseLobbyingInd00
IRS990ScheduleC/PoliticalExpendituresAmt00
IRS990ScheduleC/SubstantiallyAllDuesNondedInd00
IRS990ScheduleD/EquipmentGrp/BookValueAmt0277331
IRS990ScheduleD/EquipmentGrp/DepreciationAmt01062584
IRS990ScheduleD/EquipmentGrp/OtherCostOrOtherBasisAmt01339915
IRS990ScheduleD/ExpensesNotReportedAmt00
IRS990ScheduleD/ExpensesNotRptFinclStmtAmt00
IRS990ScheduleD/ExpensesSubtotalAmt010328608
IRS990ScheduleD/FootnoteTextInd0X
IRS990ScheduleD/LeaseholdImprovementsGrp/BookValueAmt00
IRS990ScheduleD/LeaseholdImprovementsGrp/DepreciationAmt0135020
IRS990ScheduleD/LeaseholdImprovementsGrp/OtherCostOrOtherBasisAmt0135020
IRS990ScheduleD/OtherLandBuildingsGrp/BookValueAmt03449
IRS990ScheduleD/OtherLandBuildingsGrp/DepreciationAmt034713
IRS990ScheduleD/OtherLandBuildingsGrp/OtherCostOrOtherBasisAmt038162
IRS990ScheduleD/RevenueNotReportedAmt00
IRS990ScheduleD/RevenueNotReportedFinclStmtAmt00
IRS990ScheduleD/RevenueSubtotalAmt010668958
IRS990ScheduleD/SupplementalInformationDetail/ExplanationTxt0THE ASSOCIATION BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY INCOME TAX POSITIONS TAKEN. THEREFORE, MANAGEMENT HAS NOT IDENTIFIED ANY UNCERTAIN INCOME TAX POSITIONS. GENERALLY, INCOME TAX RETURNS RELATED TO THE CURRENT AND THREE PRIOR YEARS REMAIN OPEN FOR EXAMINATION BY TAXING AUTHORITIES.
IRS990ScheduleD/SupplementalInformationDetail/FormAndLineReferenceDesc0PART X, LINE 2:
IRS990ScheduleD/TotalBookValueLandBuildingsAmt0280780
IRS990ScheduleD/TotalExpensesPerForm990Amt010328608
IRS990ScheduleD/TotalRevenuePerForm990Amt010668958
IRS990ScheduleD/TotalRevEtcAuditedFinclStmtAmt010668958
IRS990ScheduleD/TotExpnsEtcAuditedFinclStmtAmt010328608
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt00
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt10
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt01
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt10
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt02587793
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt151875
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt0EUROPE (INCLUDING ICELAND AND GREENLAND)
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt1EAST ASIA AND THE PACIFIC
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt0GENERAL ASSOCIATION MANAGEMENT - SCHEDULE MEETINGS, MEMBER SERVICES, CONFERENCE CALLSADVOCACY, GOVERNMENT AND REGULATORY AFFAIRS - ANNUAL CONFERENCE PLANNING AND OUTREACH TO STAKEHOLDERS
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt1GENERAL ASSOCIATION MANAGEMENT - SCHEDULE MEETINGS, MEMBER SERVICES, CONFERENCE CALLSADVOCACY, GOVERNMENT AND REGULATORY AFFAIRS - ANNUAL CONFERENCE PLANNING AND OUTREACH TO STAKEHOLDERSNOTE: IN JANUARY 2009 PPTA'S OFFICE IN JAPAN CLOSED AND THE CONTRACT WITH ITS SINGLE EMPLOYEE WAS TERMINATED.
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt0PROGRAM SERVICES
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt1PROGRAM SERVICES
IRS990ScheduleF/BoycottCountriesInd00
IRS990ScheduleF/ContinuationSpentAmt00
IRS990ScheduleF/ContinutationTotalEmployeeCnt00
IRS990ScheduleF/ContinutationTotalOfficeCnt00
IRS990ScheduleF/ForeignCorpOwnershipInd00
IRS990ScheduleF/ForeignPartnershipInd00
IRS990ScheduleF/InterestInForeignTrustInd00
IRS990ScheduleF/PassiveForeignInvestmestCoInd00
IRS990ScheduleF/SubtotalEmployeesCnt00
IRS990ScheduleF/SubtotalOfficesCnt01
IRS990ScheduleF/SubtotalSpentAmt02639668
IRS990ScheduleF/TotalEmployeeCnt00
IRS990ScheduleF/TotalOfficeCnt01
IRS990ScheduleF/TotalSpentAmt02639668
IRS990ScheduleF/TransferToForeignCorpInd00
IRS990ScheduleJ/BoardOrCommitteeApprovalInd0X
IRS990ScheduleJ/CompensationCommitteeInd0X
IRS990ScheduleJ/EquityBasedCompArrngmInd00
IRS990ScheduleJ/HousingAllowanceOrResidenceInd0X
IRS990/ScheduleJRequiredInd01
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BaseCompensationFilingOrgAmt0153547
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BaseCompensationFilingOrgAmt1120000
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BaseCompensationFilingOrgAmt2250836
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BaseCompensationFilingOrgAmt3185645
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BaseCompensationFilingOrgAmt4221251
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BaseCompensationFilingOrgAmt5213051
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BaseCompensationFilingOrgAmt6150000
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BaseCompensationFilingOrgAmt7101795
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BaseCompensationFilingOrgAmt8156129
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BonusFilingOrganizationAmount0256879
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BonusFilingOrganizationAmount121600
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BonusFilingOrganizationAmount272000
IRS990ScheduleJ/RltdOrgOfficerTrstKeyEmplGrp/BonusFilingOrganizationAmount353000

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings

Displayed year

2014 • Form 990Detailed filing. Detailed filing data is available for this year.

Open filing
Assets
$5,430,703
Liabilities
$2,264,745
Net assets
$3,165,958
Revenue
$10,668,958
Expenses
$10,328,608
Net income
$340,350
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2024Facts available. Structured filing facts are available, but richer extracted sections are limited.$12.8$4.74$8.05$15.0$16.2$1.20
2023Detailed filing. Detailed filing data is available for this year.$12.2$3.20$8.95$15.0$14.4$0.56
2022Detailed filing. Detailed filing data is available for this year.$10.7$2.29$8.40$16.1$13.1$3.04
2021Detailed filing. Detailed filing data is available for this year.$7.83$2.47$5.36$13.0$14.5$1.51
2020Detailed filing. Detailed filing data is available for this year.$9.83$2.96$6.87$12.4$11.3$1.09
2019Detailed filing. Detailed filing data is available for this year.$9.10$3.32$5.78$13.4$12.6$0.81
2018Detailed filing. Detailed filing data is available for this year.$8.01$3.04$4.97$12.7$13.7$0.98
2017Detailed filing. Detailed filing data is available for this year.$9.06$3.12$5.95$12.4$11.8$0.56
2016Detailed filing. Detailed filing data is available for this year.$7.59$2.20$5.38$11.7$10.6$1.09
2015Detailed filing. Detailed filing data is available for this year.$6.18$1.89$4.29$11.4$10.0$1.35
2014Detailed filing. Detailed filing data is available for this year.$5.43$2.26$3.17$10.7$10.3$0.34
2013Summary only. Only limited summary data is available for this year.$5.10$2.27$2.82$10.4$11.0$0.53
2012Summary only. Only limited summary data is available for this year.$6.04$2.74$3.30$10.4$11.1$0.67
2011Summary only. Only limited summary data is available for this year.$5.87$1.88$3.99$10.3$10.3$0.05